139 related articles for article (PubMed ID: 11883698)
1. Technology evaluation: APC-8015, Dendreon.
Rini BI
Curr Opin Mol Ther; 2002 Feb; 4(1):76-9. PubMed ID: 11883698
[TBL] [Abstract][Full Text] [Related]
2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Lin AM; Hershberg RM; Small EJ
Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
6. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
[TBL] [Abstract][Full Text] [Related]
8. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
10. Technology evaluation: DCVax, Northwest Biotherapeutics.
Knutson KL
Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
13. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
14. DC therapy for prostate cancer.
Swindle PW; Tepes S; Clements J
Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
16. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccines for prostate cancer: a review of clinical data.
Arlen PM; Gulley JL
Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
[TBL] [Abstract][Full Text] [Related]
18. GVAX (Cell Genesys).
Dummer R
Curr Opin Investig Drugs; 2001 Jun; 2(6):844-8. PubMed ID: 11572668
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: APC-80200, Dendreon.
Rice A; Hart D
Curr Opin Mol Ther; 2002 Oct; 4(5):523-7. PubMed ID: 12435055
[TBL] [Abstract][Full Text] [Related]
20. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
